ORIC updates $200M at-the-market stock program

Rhea-AI Filing Summary

FAQ

Filing Exhibits & Attachments

Q: How much has ORIC Pharmaceuticals (ORIC) already raised under its ATM program?

Q: What role does Jefferies play in ORIC Pharmaceuticals’ (ORIC) stock sales?

Q: Which legal firm provided the opinion for ORIC Pharmaceuticals’ (ORIC) new ATM offering?

8-K Event Classification

What stock offering did ORIC Pharmaceuticals (ORIC) describe in this 8-K?

How much has ORIC Pharmaceuticals (ORIC) already raised under its ATM program?

What is the purpose of the 2026 prospectus supplement for ORIC Pharmaceuticals (ORIC)?

What role does Jefferies play in ORIC Pharmaceuticals’ (ORIC) stock sales?

Which legal firm provided the opinion for ORIC Pharmaceuticals’ (ORIC) new ATM offering?

Does ORIC Pharmaceuticals (ORIC) plan further sales under the 2024 prospectus supplement?

ORIC Pharmaceuticals has already sold 13,478,432 common shares for approximately $139.7 million in gross proceeds. These sales were completed under a 2024 prospectus supplement, and the company will not make any additional sales under that earlier supplement.

Jefferies LLC acts as sales agent under ORIC Pharmaceuticals’ at-the-market offering program. It facilitates the periodic sale of ORIC’s common shares into the market pursuant to the Sales Agreement and the applicable prospectus supplements filed with the SEC.

Wilson Sonsini Goodrich & Rosati, P.C. provided the legal opinion for the shares offered under ORIC’s 2026 prospectus supplement. That opinion is filed as Exhibit 5.1, with a related consent included as Exhibit 23.1 in the same report.

ORIC Pharmaceuticals, Inc. is offering up to $200.0 million of common shares through a renewed at-the-market program under its existing Sales Agreement with Jefferies LLC, supported by a new 2026 prospectus supplement under its automatic shelf registration.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

ORIC Pharmaceuticals, Inc. is offering up to $200.0 million of common shares through a renewed at-the-market program under its existing Sales Agreement with Jefferies LLC, supported by a new 2026 prospectus supplement under its automatic shelf registration.

The company previously sold 13,478,432 shares for approximately $139.7 million in gross proceeds under a 2024 prospectus supplement, and no further sales will occur under that earlier supplement. A legal opinion from Wilson Sonsini Goodrich & Rosati related to the new offering is filed as an exhibit.

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

ORIC Pharmaceuticals described a renewed at-the-market stock offering of up to $200.0 million of common shares. The sales occur under its existing Sales Agreement with Jefferies LLC, supported by a new 2026 prospectus supplement filed under an automatic shelf registration.

ORIC Pharmaceuticals has already sold 13,478,432 common shares for approximately $139.7 million in gross proceeds. These sales were completed under a 2024 prospectus supplement, and the company will not make any additional sales under that earlier supplement.

The 2026 prospectus supplement supports the offer and sale of up to $200.0 million of ORIC’s common shares under its at-the-market Sales Agreement. It updates the company’s disclosure framework for future issuances under its automatic shelf registration statement.

Jefferies LLC acts as sales agent under ORIC Pharmaceuticals’ at-the-market offering program. It facilitates the periodic sale of ORIC’s common shares into the market pursuant to the Sales Agreement and the applicable prospectus supplements filed with the SEC.

Wilson Sonsini Goodrich & Rosati, P.C. provided the legal opinion for the shares offered under ORIC’s 2026 prospectus supplement. That opinion is filed as Exhibit 5.1, with a related consent included as Exhibit 23.1 in the same report.

ORIC Pharmaceuticals does not plan additional sales under the 2024 prospectus supplement. The company states that no further shares will be sold under that document, shifting future at-the-market issuances to the newly filed 2026 prospectus supplement instead.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/23/2026 - 05:06 PM EST

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

February 23, 2026

ORIC Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-39269

47-1787157

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

240 E. Grand Ave, 2nd Floor

South San Francisco, CA 94080

(Address of principal executive offices, including zip code)

(650) 388-5600

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common stock, par value $0.0001 per share

ORIC

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01

Other Events.

On May 6, 2021, ORIC Pharmaceuticals, Inc. (the “Company”) entered into an Open Market Sale Agreement^SM (the “Sales Agreement”) with Jefferies LLC (“Jefferies”) to sell shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), from time to time, through an “at the market offering” program under which Jefferies acts as sales agent. The Shares are issued pursuant to the Company’s effective shelf registration statement on Form S-3ASR (File No. 333-277829), filed on March 11, 2024, which became automatically effective upon filing with the Securities and Exchange Commission (the “SEC”). On March 11, 2024, the Company filed a prospectus supplement (the “2024 Prospectus Supplement”) with the SEC in connection with the offer and sale of up to $200.0 million of Shares pursuant to the Sales Agreement. As of February 23, 2026, the Company had sold 13,478,432 of Shares for gross proceeds of approximately $139.7 million, before deducting commissions to Jefferies and other expenses, under the 2024 Prospectus Supplement.

On February 26, 2026, the Company filed a prospectus supplement with the SEC in connection with the offer and sale of up to $200.0 million of Shares pursuant to the Sales Agreement (the “2026 Prospectus Supplement”). No further sales of shares will be made under the 2024 Prospectus Supplement.

The legal opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation, relating to the Shares being offered in connection with the 2026 Prospectus Supplement is filed as Exhibit 5.1 to this Current Report on Form 8-K.

This Current Report shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.


Exhibit Number		Description

5.1		Opinion of Wilson Sonsini Goodrich & Rosati, P.C.

23.1		Consent of Wilson Sonsini Goodrich & Rosati, P.C. (included in Exhibit 5.1)

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Source: View Original Filing on SEC EDGAR

ORIC PHARMACEUTICALS, INC.

Date: February 23, 2026

/s/ Christian V. Kuhlen

Christian V. Kuhlen, M.D., J.D.

General Counsel

4 documents